Medaysis
Enable Innovation

DATA SHEET

Mouse Anti-Nectin 4/PVRL4 [MD247]: MC0478, MC0478RTU7

Intended Use: For Research Use Only

Description: Homologous to the poliovirus receptor (PVR/CD155), the nectin immunoglobulin superfamily comprises four known isoforms (-1, -2, -3, and -4). The ectodomain of nectin family members comprises three Ig-like domains (V, C, C). Nectins localize at the adherens junctions (AJ) in epithelial and endothelial cells where they serve as adhesion molecules. Actin-based AJs play a role in mechanical adhesion, cellular morphogenesis and cellular differentiation. Nectin associates with the actin cytoskeleton through its interaction with the actin filament-binding protein afadin. Nectin 4 and afadin co-localize at cadherin-based adherens junctions in MDCKII epithelial cells. Nectin 4 and nectin 3 share a common binding region in the V domain of Nectin 1 and thus compete for Nectin 1 binding. The Nectin 3/4 binding domain maps to the C-C'-C"-D strands of the V domain of Nectin 1. Unlike other nectins, which are more widely expressed, Nectin 4 is mainly expressed in the placenta.

Specifications

Clone:	MD247
Source:	Mouse
Isotype:	IgG2a/k
Reactivity:	Human
Immunogen:	Recombinant fragment aa1-200 of human NECTIN4 protein
Localization:	Membrane
Formulation:	Purified antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC

Package:

Description	Catalog No.	Size
Nectin 4/PVRL4 [MD247] Concentrated	MC0478	1 ml
Nectin 4/PVRL4 [MD247] Prediluted	MC0478RTU7	7 ml

IHC Procedure*

Positive Control Tissue:	Tonsil, placenta or breast
Concentrated Dilution:	50-200
Pretreatment:	Tris EDTA pH9.0, 15 minutes Pressure Cooker or 30-60 minutes water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human placenta stained with Nectin 4 using DAB

References:

1. NECTIN4 Expression in Extramammary Paget's Disease: Implication of a New Therapeutic Target. Murata M, et al. Int J Mol Sci 21:N/A, 2020.
2. NECTIN4 (PVRL4) as Putative Therapeutic Target for a Specific Subtype of High Grade Serous Ovarian Cancer-An Integrative Multi-Omics Approach. Bekos C, et al. Cancers (Basel) 11:N/A, 2019.

Orders: customercare@medaysis.com Support: techsupport@medaysis.com Tel: 510-509-3153 www.medaysis.com

© Medaysis Company